Denali Therapeutics (DNLI)
(Real Time Quote from BATS)
$24.88 USD
+0.19 (0.77%)
Updated Nov 25, 2024 03:42 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
DNLI 24.88 +0.19(0.77%)
Will DNLI be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DNLI
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
Other News for DNLI
Denali Therapeutics Advances Brain Disease Therapies
Denali Has A Neurodegenerative Edge Despite Market Skepticism
FMR LLC Expands Stake in Denali Therapeutics Inc
Oppenheimer Sticks to Their Buy Rating for Denali Therapeutics (DNLI)
Capital Research Global Investors Expands Stake in Denali Therapeutics Inc.